ICR

Kyoto, Japan
Kyoto, Japan

Time filter

Source Type

NEW YORK--(BUSINESS WIRE)--ICR today announced that it has made major investments to further expand its presence on the West Coast, building upon its strong foundation and momentum in the market place. The firm has added Kevin Faulkner as Managing Director, to lead West Coast Tech IR, and Merrill Freund, Managing Director, to lead West Coast Tech PR efforts. Both professionals bring over 20 years of senior level experience in their respective fields, as well as a proven track record in helping companies optimize brand and equity value. The teams being led by Kevin and Merrill serve as part of ICR’s dedicated technology group, which is comprised of over 30 professionals and specialists with expertise spanning the spectrum of tech-driven industries. “We are thrilled to have hired two very talented and experienced leaders to help ICR take its West Coast presence to the next level. This is an incredibly strategic geographic area for the firm, and our increased investments reflect a commitment to extending our market leadership position,” said Tom Ryan, CEO of ICR. “Our firm is highly differentiated in its ability to deliver integrated communications and transaction advisory services to technology clients at every stage of the lifecycle, and we believe the addition of Kevin and Merrill to the ICR team is great news for clients in this market.” Kevin Faulkner was most recently Vice President of Investor Relations at Apigee, following the company’s IPO and leading up to its acquisition by Google. He was previously a Senior Vice President of Investor Relations with BEA Systems. During his 10 years with BEA, the company’s revenue scaled from over $150 million to more than $1.5 billion at the time it was acquired by Oracle for $8.5 billion. Faulkner also served as a spokesperson for investor, customer, partner, industry analyst, press and employee communications, and served as member of the company’s senior management team. Additionally, he spent 6 years as Vice President of Investor Relations at Nuance Communications, during which time the company’s revenue increased from over $250 million to over $2 billion. Faulkner spent the first decade of his career as a Corporate and Securities Attorney with several firms, including Wilson Sonsini Goodrich & Rosati and Morrison & Foerster, where he worked on a range of IPOs, M&A transactions, and general corporate matters for technology companies. Merrill Freund most recently ran his own tech PR agency, from which he brought his team, including Anna Vaverka, and roster of clients to ICR. Freund spent 20 years with Schwartz Communications (acquired by MSL Group), where he led the San Francisco office and served as Executive Vice President and Managing Director for one of the largest tech PR agencies on the West Coast. At Schwartz, Freund led a 60-person team servicing emerging growth technology companies in industries including cloud computing, big data analytics, enterprise software, mobile, and data center infrastructure. During his career, Freund has represented start-ups as well as Fortune 500 companies, in each case helping them define and differentiate company stories in addition to dramatically increasing awareness and brand value. “ICR continues lead the market in software and security related IPOs with recent advisory engagements including MuleSoft, Alteryx, Yext and Appian,” said Tim Dolan, Head of ICR’s Technology Group. “We are excited to have Kevin and Merrill join our team to help West Coast technology companies optimize their messaging and scale their communications programs based on their substantial experience.” ICR’s services platform includes IPO advisory, investor relations, public relations, creative services/digital branding, IPO roadshow videos, and crisis/special situations management. ICR has advised more companies through the IPO process than any peer and has built one of the largest communications platforms in the world servicing more than 20 industries, with technology being the largest. O’Dwyer’s, a leading PR and communications industry publication, ranks ICR as a Top 10 provider of Technology and Industrials communications services. Established in 1998, ICR partners with companies to optimize transactions and execute strategic communications programs that achieve business goals, build credibility and enhance long-term enterprise value. The firm’s highly differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 500 clients in approximately 20 industries. Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America maintaining offices in New York, Norwalk, Los Angeles, Boston, San Francisco, Hong Kong and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.


News Article | June 22, 2017
Site: www.businesswire.com

NEW YORK--(BUSINESS WIRE)--ICR, a top-five ranked public relations firm, is pleased to announce that it won the Public Relations Society of America-New York’s (“PRSA-NY”) prestigious 2017 Big Apple Award for Reputation and Brand Management: “Campaigns with Budgets of $150,000 or Less” for the corporate communications campaign it designed and executed for U.S. Concrete, Inc. (NASDAQ: USCR), a leading national producer of ready-mixed concrete. “This award reflects the breadth of knowledge that permeates throughout our firm and our commitment to excellence, which are key reasons clients chose to partner with us,” said Tom Ryan, Chief Executive Officer of ICR. “What differentiates ICR is our inherent ability to bring substantial value to our clients by leveraging our deep understanding of the 20 diverse sectors in which we specialize and our strong media relationships to raise awareness and support for their strategy, brand and management teams. I’m very proud of our building materials team for the tremendous results they have delivered – and continue to deliver – for U.S. Concrete.” In total, more than one billion impressions were garnered as a result of the media campaign ICR designed and executed for U.S. Concrete over the course of 2016, with its share of voice surging nearly 87 percent over 2015 levels. Among the many highlights of the 2016 campaign included: “We are very proud of our partnership with U.S. Concrete and the value we have created for them,” said Phil Denning, Partner at ICR and head of its building materials team. “We are honored that PRSA-NY recognized our efforts and bestowed upon us the Big Apple Award. We look forward to competing again next year given the high number of impressions we have already generated for the Company in 2017 with multiple appearances on Mad Money, Morning’s with Maria, Bloomberg TV, Bloomberg Radio and more.” "Our excellent partnership with ICR has generated tremendous attention through top-tier media regarding our company's performance and growth opportunities including the U.S. infrastructure rebuild,” said Jody Tusa, Senior Vice President and Chief Financial Officer of U.S. Concrete. “I give them an A+ for their media contacts, preparation and orchestration of our campaign. They have helped us achieve a higher profile, a major objective of the company." Established in 1998, ICR partners with companies to optimize transactions and execute strategic communications programs that achieve business goals, build credibility and enhance long-term enterprise value. The firm’s highly differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 500 clients in approximately 20 industries. Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America maintaining offices in New York, Norwalk, Los Angeles, Boston, San Francisco, Hong Kong and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR. PRSA-NY established the Big Apple Awards in 1987 to celebrate excellence in public relations. Widely regarded as one of the industry’s most prestigious accolades, the Big Apple Awards honor innovative and strategic PR campaigns and projects. The Public Relations Society of America, New York City chapter is the industry go-to organization for knowledge and networking for communications professionals in the New York metro area. Established in 1947, PRSA-NY is one of the founding chapters of the Public Relations Society of America, the world’s largest professional organization for public relations practitioners, and the third largest PRSA local chapter in the U.S. It serves the interests of public relations professionals working in business and industry, counseling firms, government, associations, hospitals, schools, professional services firms and nonprofit organizations. Chapter board and committee members are volunteer public relations professionals who work in the New York metropolitan area. For more information, please visit our website and follow us on Facebook, Twitter and LinkedIn.


News Article | July 20, 2017
Site: www.businesswire.com

纽约与北京--(BUSINESS WIRE)--(美国商业资讯)--领先的策略传播和咨询公司ICR今日宣布,任命资本市场资深人士Robin Yang担任董事总经理。作为ICR亚洲公司策略咨询业务高管团队成员,Yang女士将执掌数字新媒体(TMT)和消费领域的投资关系事务,并为ICR一体化公共关系和数字媒体项目领域不断增长的服务产品提供支持。 ICR亚洲业务负责人Bill Zima表示,“我们非常高兴能够将Robin纳入麾下,并借此加强我们在亚洲的实力和领导地位。自 2006年以来,亚洲一直是ICR的重点关注市场。Robin曾担任过多个重要资本市场职位,也曾担任高管职务,这些全面的经验为她提供了强有力的后盾,有助于其了解客户所面临的挑战,并通过精心规划和实施高端全球传播策略来提升价值。” Yang女士在机构资本市场、融资和会计领域拥有16年的经验。在职业生涯初期,她曾担任卖方研究分析师,负责美国企业软件部门的分析业务。随后,她曾担任跨行业买方分析师,负责大中华地区的投资机遇分析。在这之后,她曾在多家快速增长的中国技术企业中担任首席财务官和咨询师,为中国公司的跨境资本筹集和并购提供咨询服


News Article | July 25, 2017
Site: www.businesswire.com

NEW YORK--(BUSINESS WIRE)--ICR, Richard Jaffe and Shoptalk announced they will be partnering to host the 9th Annual Retail Summer School at Columbia Business School. The event will take place on Wednesday August 2nd, and is designed to educate and inform professionals and investors in the retail industry about the important issues and ideas that are impacting results and providing opportunities. The event was created by former equity research analyst Richard Jaffe in 2008, and past speakers have included professors whose ideas on retail had been recently published, innovators in the areas of technology, IT and logistics, leaders of new, cutting edge retail concepts, and professionals who were experts in various aspects of retailing. This year, the format of the event includes presentations, panel discussions, fireside chats and Q+A. This year’s preliminary agenda, “Retail Disruption and the Opportunities that Arise,” is as follows: Established in 1998, ICR partners with companies to optimize transactions and execute strategic communications programs that achieve business goals, build credibility and enhance long-term enterprise value. The firm’s highly differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 500 clients in approximately 20 industries. Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America maintaining offices in New York, Norwalk, Los Angeles, Boston, San Francisco, Hong Kong and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.


News Article | August 1, 2017
Site: www.businesswire.com

NEW YORK--(BUSINESS WIRE)--ICR, Richard Jaffe and Shoptalk announced they will be partnering to host the 9th Annual Retail Summer School at Columbia Business School. The event will take place on Wednesday August 2nd, and is designed to educate and inform professionals and investors in the retail industry about the important issues and ideas that are impacting results and providing opportunities. The event was created by former equity research analyst Richard Jaffe in 2008, and past speakers have included professors whose ideas on retail had been recently published, innovators in the areas of technology, IT and logistics, leaders of new, cutting edge retail concepts, and professionals who were experts in various aspects of retailing. This year, the format of the event includes presentations, panel discussions, fireside chats and Q+A. This year’s preliminary agenda, “Retail Disruption and the Opportunities that Arise,” is as follows: Established in 1998, ICR partners with companies to optimize transactions and execute strategic communications programs that achieve business goals, build credibility and enhance long-term enterprise value. The firm’s highly differentiated service model, which pairs capital markets veterans with senior communications professionals, brings deep sector knowledge and relationships to more than 500 clients in approximately 20 industries. Today, ICR is one of the largest and most experienced independent communications and advisory firms in North America maintaining offices in New York, Norwalk, Los Angeles, Boston, San Francisco, Hong Kong and Beijing. Learn more at www.icrinc.com. Follow us on Twitter at @ICRPR.


News Article | March 1, 2017
Site: www.businesswire.com

JACKSONVILLE, Fla. & NEW YORK--(BUSINESS WIRE)--Regency Centers Corporation (NYSE: REG) (“Regency”) and Equity One, Inc. (NYSE: EQY) (“Equity One”) today announced the completion of their previously announced merger, whereby Equity One merged with and into Regency, with Regency continuing as the surviving public company. The merger forms a combined company with a total market capitalization of approximately $16 billion. Beginning March 2, 2017, Regency will be a member of the S&P 500 index. “We are delighted to announce the completion of our merger with Equity One, further establishing Regency Centers as the preeminent national shopping center REIT,” stated Martin E. “Hap” Stein, Jr., Chairman and Chief Executive Officer. “With a high quality portfolio of 429 properties located in many of the country’s top markets, featuring outstanding demographics, augmented by a best-in-class development and redevelopment program, we believe Regency offers a unique long-term growth profile. Further, as we have stated before, we expect the transaction to be accretive to core FFO per share while preserving our sector-leading balance sheet. Moving ahead, we look forward to the rapid integration of the two platforms and to creating additional value for our shareholders over the quarters and years to come.” The completion of the transaction follows the satisfaction of all conditions to the closing of the merger, including receipt of approvals of the merger and other merger-related proposals by Regency and Equity One stockholders, which approvals were obtained on February 24, 2017. Pursuant to the terms of the definitive merger agreement entered into by and between Regency and Equity One on November 14, 2016, Equity One stockholders are entitled to receive 0.45 of a newly issued share of Regency common stock for each share of Equity One common stock that they owned immediately prior to the effective time of the merger. The common stock of the combined company will trade under the symbol “REG” on the NYSE, and the Equity One common stock will be suspended from trading on the NYSE effective as of the opening of trading on March 2, 2017. In connection with the completion of the merger, the Regency board of directors has appointed Joseph Azrack, Chaim Katzman and Peter Linneman, former Equity One directors, to serve on Regency’s board. Mr. Katzman, the former Chairman of Equity One’s board, will serve as non-executive Vice Chairman of the Regency board. Regency’s current executive officers will continue to serve in their current positions. Following the merger, Regency now expects the combined portfolio to produce annual Same Property NOI growth for 2017 within a new range of 3.0% to 3.8%. This compares to previous guidance for Regency as a stand-alone entity of 2.25% to 3.00%. Regency expects to realize annualized cost savings of approximately $27 million by 2018, primarily related to the elimination of duplicative corporate and property-level operating costs. The transaction is expected to be accretive to Core FFO, assuming the anticipated full cost benefits, before the positive incremental impacts of merger-related purchase accounting adjustments, and after potential dispositions. Regency will update its guidance more completely when it reports first quarter 2017 results. J.P. Morgan Securities LLC acted as financial advisor, and Wachtell, Lipton, Rosen & Katz acted as legal advisor, to Regency in connection with the merger. Barclays Capital Inc. acted as lead financial advisor, Citigroup Global Markets Inc. acted as co-financial advisor, and Kirkland & Ellis LLP acted as legal advisor to Equity One in connection with the merger. ICR, LLC served as communications advisor for the transaction. Regency is the preeminent national owner, operator and developer of neighborhood and community shopping centers which are primarily anchored by productive grocers and located in affluent and infill trade areas in the country’s most attractive metro areas. As of December 31, 2016, Regency’s portfolio of 307 retail properties encompassed over 42.2 million square feet, which includes properties held in co-investment partnerships. Regency has developed 225 shopping centers since 2000, representing an investment at completion of more than $3.5 billion. Operating as a fully integrated real estate company, Regency is a qualified real estate investment trust that is self-administered and self-managed. About Equity One, Inc. As of December 31, 2016, Equity One’s portfolio comprised 122 properties, including 101 retail properties and five non-retail properties totaling approximately 12.8 million square feet of gross leasable area, or GLA, 10 development or redevelopment properties with approximately 2.3 million square feet of GLA, and six land parcels. As of December 31, 2016, Equity One’s retail occupancy excluding developments and redevelopments was 95.8% and included national, regional and local tenants. Additionally, Equity One had joint venture interests in six retail properties and two office buildings totaling approximately 1.4 million square feet of GLA. The information presented herein may contain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 giving Regency’s or Equity One’s expectations or predictions of future financial or business performance or conditions. Forward-looking statements are typically identified by words such as “believe,” “expect,” “anticipate,” “intend,” “target,” “estimate,” “continue,” “positions,” “prospects” or “potential,” by future conditional verbs such as “will,” “would,” “should,” “could” or “may”, or by variations of such words or by similar expressions. These forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. Forward-looking statements speak only as of the date they are made and we assume no duty to update forward-looking statements. As forward-looking statements involve significant risks and uncertainties, caution should be exercised against placing undue reliance on such statements. In addition to factors previously disclosed in Regency’s and Equity One’s reports filed with the Securities and Exchange Commission and those identified elsewhere in this communication, the following factors, among others, could cause actual results to differ materially from forward-looking statements and historical performance: the outcome of any legal proceedings that are or may be instituted against Regency or Equity One; the possibility that the anticipated benefits of the transaction are not realized when expected or at all, including as a result of the impact of, or problems arising from, the integration of the two companies or as a result of changes in the economy and competitive factors in the areas where Regency and Equity One do business; diversion of management’s attention from ongoing business operations and opportunities; potential adverse reactions or changes to business or employee relationships, including those resulting from the completion of the transaction; Regency’s ability to complete the integration of Equity One successfully or fully realize cost savings and other benefits and other consequences associated with mergers, acquisitions and divestitures; changes in asset quality and credit risk; the potential liability for a failure to meet regulatory requirements, including the maintenance of REIT status; material changes in the dividend rates on securities or the ability to pay dividends on common shares or other securities; potential changes to tax legislation; changes in demand for developed properties; adverse changes in financial condition of joint venture partner(s) or major tenants; risks associated with the acquisition, development, expansion, leasing and management of properties; risks associated with the geographic concentration of Regency; risks associated with the concentration of tenants; the impact of the transactions on relationships, including with tenants, employees, customers and competitors; significant costs related to uninsured losses, condemnation, or environmental issues; the ability to retain key personnel; and changes in local, national and international financial market, insurance rates and interest rates. Regency does not intend, and undertakes no obligation, to update any forward-looking statement.


News Article | February 15, 2017
Site: www.nature.com

C57BL/6N mice, ICR mice and Wistar rats were purchased from SLC Japan (Shizuoka, Japan). All animals were maintained under specific pathogen-free conditions. All animal experiments were approved by the Insititutional Animal Care and Use Committee, and performed in accordance with the guidelines of the University of Tokyo and the National Institute for Physiological Sciences. Diabetes was induced in 8-week-old C57BL/6N male mice by intravenous injection of 150 mg kg−1 of STZ. Mice with nonfasting blood glucose levels over 350 mg dl−1 1 week after STZ administration were used. Embryo culture and manipulation are described11. Rodent islets conventionally are isolated by collagenase perfusion of the pancreata through the common bile duct. However, the pancreata of Pdx1mu/mu chimaeric rats could not be perfused in this way because the pancreaticobiliary junction was maldeveloped in all (Extended Data Fig. 5). Therefore, we isolated islets by digestion of minced pancreata with collagenase. Pancreata removed from interspecific chimaera were inflated by interstitial injection of Gey’s balanced salt solution (GBSS; Sigma-Aldrich). GBSS-filled pancreata were minced using scissors. Small pieces of chopped pancreata were digested with collagenase XI (Sigma-Aldrich) to release islets from exocrine tissue. After 6–8 min incubation, islets were picked up using glass micropipettes and transplanted beneath the kidney capsule of 10-week-old male mice with STZ-induced diabetes, as previously described11. To prevent acute graft rejection, 0.5 mg per g (body weight) per day of tacrolimus, was injected intraperitoneally on the day of transplantation and on each of the following 4 days, in addition to an anti-inflammatory cocktail (all components, Affymetrix) containing anti-mouse interferon-γ mAb (rat IgGκ, 16-7312, clone R4-6A2), anti-mouse tumour necrosis factor-α mAb (rat IgG1κ, 16-7322, clone MP6-XT3) and anti-mouse IL-1β (hamster IgG, 16-7012, clone B122). The mRNA of TALENs (left and right) and rat Exo1 were generated by in vitro transcription. Linearized plasmids were transcribed from T7 promoter using mMESSAGE mMACHINE T7 ULTRA Transcription Kit (Thermo Fisher Scientific) and resultant mRNAs were cleaned up by MEGAclear Kit (Thermo Fisher Scientific). 3 or 10 ng μl−1 of each mRNA was prepared by dilution in RNase- free-water and mixture of right TALEN, left TALEN and Exo1 were injected into the male pronuclei of zygotes by microinjection, as previously reported18. TALEN potential off-target sites were predicted by TALENoffer software. We chose 21 candidates (5 in exonic loci, 13 in intronic loci, 3 in intergenic loci) from TOP200 candidates19. We performed PCR amplification of genomic DNA from Pdx1+/muA, Pdx1+/muB and wild-type Wistar rats, subjecting the amplicons to Sanger sequencing. Genomic DNA was isolated from fluorescent-marker-negative cells isolated by FACS from chimaeric-rat blood samples. The TALEN target region of Pdx1 was amplified by PCR using the following primers: (forward) 5′-GCTGAGAGTCCGTGAGCTGCCCAG-3′ and (reverse) 5′-GGAACGCTTAAAGATCGTAGCAGC-3′). The PCR products were sequenced. Total RNA was isolated from duodenum of Pdx1muA/muB mice and reverse-transcribed by Superscript III reverse transcriptase (Thermo Fisher Scientific) with oligodT primer. Pdx1muA or Pdx1muB full-length cDNA were amplified by PCR using the following primers: (forward) 5′-GGCGCTGAGAGTCCGTGAGCTGC-3′ and (reverse) 5′-TTTTTTTTTTTTTTTGAAACCTCAAACAG-3′. Nonfasting blood glucose levels were determined (Medisafe-Mini glucometer; Terumo) weekly after islet transplantation. GTTs in overnight-fasted chimaera rats was conducted 0, 15, 30, 60 and 120 min after intraperitoneal injection of glucose (50% d-glucose solution, 2.5 g per kg body weight). Tail-vein blood was sampled by phlebotomy. Non-fasting serum mouse or rat c-peptide levels were analysed by enzyme-linked immunosorbent assay (ELISA) (mouse c-peptide ELISA kit, Shibayagi and Morinaga Institute of Biological Science; rat c-peptide ELISA kit, MERCODIA AB). Serum was isolated from 10-week-old Pdx1muA/muB + mPSCs chimaeras, C57BL/6N mice and Wistar rats. Serum was obtained from STZ-treated diabetic mice transplanted with mouseR islets 260 or 372 days after transplantation. SGE2 (EGFP-expressing mES cells) were derived from blastocysts generated from mating C57BL/6N female mice with C57BL/6N-Tg male mice (CAG-EGFP) (SLC Japan). mRHT (mES cells) were derived from blastocysts generated from mating male and female H2B-tdTomato knock-in mice with human histone H2B and tdTomato fusion gene in the mouse ROSA locus (T.K., unpublished data). Wlv3i-1 (rES cells) and GT3.2 (miPSCs) have been previously described11, 31. Maintenance of mPSCs and rPSCs has been previously described32, 33. Briefly, mPSCs were cultured on mitomycin-C-treated mouse embryonic fibroblasts in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 0.1 mM 2-mercaptoethanol, 0.1 mM nonessential amino acids, 1 mM sodium pyruvate, and 1,000 units per ml of mouse leukaemia inhibitory factor (all Thermo Fisher Scientific) and 1% l-glutamine-penicillin-streptomycin (Sigma-Aldrich). rPSCs were cultured on mitomycin-C-treated mouse embryonic fibroblasts in N2B27 medium supplemented with 1 μM mitogen-activated protein kinase inhibitor PD0325901 and 3 μM glycogen synthase kinase inhibitor CHIR99021 (both Axon Groeningen). All PSC lines were authenticated by chimaera formation. These cell lines were not contaminated with mycoplasma. Isolated pancreata and islets were fixed in 4% paraformaldehyde in phosphate-buffered saline solution (PBS). Paraffin-embedded sections were incubated with blocking buffer (Active Motif) for 1 h at room temperature. The sections were incubated with primary antibodies, diluted in blocking buffer for 1 h at room temperature, and washed three times with PBS. They were then incubated with secondary antibodies for 1 h at room temperature. Primary antibodies used were guinea pig anti-insulin (Abcam; ab7842), rabbit anti-glucagon (Nichirei Bioscience, 422271), rabbit anti-somatostatin (Nichirei Bioscience 422651), rabbit anti-cytokeratin 19 (Abcam; ab52625, clone EP1580Y), mouse anti-amylase (SantaCruz; SC-46657, clone G-10) and goat anti-GFP (Abcam; ab6673), with Alexa-488-, Alexa-546-, and Alexa-633-conjugated secondary antibodies (Thermo Fisher Scientific). After antibody treatment, sections were mounted with Vectashield (Vector Laboratories), a mounting medium containing DAPI (Thermo Fisher Scientific) for nuclear counterstaining, and sections were observed under fluorescence microscopy. Three to five sections per slide were imaged and processed using Image J. For detection of lymphoid infiltration, DAB immunohistochemistry was performed with rabbit anti-CD3 (Abcam; ab5690) and rabbit anti-CD11b (Bioss Inc.; bs-1014R). Islets or small pieces of kidney that included transplanted islets were dispersed into single cells with collagenase type1A (Sigma-Aldrich). Dispersed cells stained with phycoerythrin (PE)-conjugated anti-mouse CD31 (Thermo Fisher Scientific; A16201, clone 390) or allophycocyanin (APC)-conjugated anti-rat CD31 (Thermo Fisher Scientific; 50-0310-82, clone TLD-3A12) were subjected to FACS CantoII analysing (BD Biosciences). Data were collected for all of the dispersed cells and analysed. The experiments were not randomized and the investigators were not blinded to allocation during experiments and outcome assessment. Sample size was estimated on the basis of previous publications. Statistical significance was calculated by F-test and Student’s t-test (compare two groups) and the similarity to the Mendelian ratio was analysed by chi-square test (with Excel and Graphpad Prism software). P < 0.05 was considered to be statistically significant. Data are presented as mean ± s.d. Immunohistochemistry and flow-cytometry studies were repeated three times independently with similar results. All relevant data that are included with this study are available from corresponding auther upon reasonable request.


News Article | January 4, 2017
Site: globenewswire.com

SALT LAKE CITY, Jan. 04, 2017 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), announced today that Darren Jensen, the Company's President and Chief Executive Officer will be presenting at the ICR Conference 2017, to be held January 9-11, 2017, at the JW Marriott Orlando Grande Lakes in Orlando, Florida. LifeVantage Corporation’s investor presentation is scheduled for Wednesday, January 11, 2017, at 10:00 a.m. Eastern Time. The presentation will be webcast live and archived on the Investor Info portion of the Company's website at http://investor.lifevantage.com/events.cfm. LifeVantage Corporation (Nasdaq:LFVN), is a science-based direct selling company dedicated to visionary science that looks to transform health, wellness and anti-aging internally and externally at the cellular level. The company is the maker of Protandim® Nrf2 and NRF1 Synergizers, its line of scientifically-validated dietary supplements, the TrueScience® Anti-Aging Skin Care Regimen, Canine Health®, the AXIO® energy product line and the PhysIQ™ Smart Weight Management System. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah.  www.lifevantage.com


News Article | March 1, 2017
Site: phys.org

Coloring hair has become a common practice, particularly for people who want to hide their graying locks. But an ingredient in many of today's commercial hair dyes has been linked to allergic reactions and skin irritation. Now scientists have developed a potentially safer alternative by mimicking the hair's natural color molecule: melanin. Their report appears in the journal ACS Biomaterials Science & Engineering. The permanent hair dye ingredient p-phenylenediamine (PPD) has been associated, although rarely, with allergic reactions including facial swelling and rashes. Coloring hair with natural melanin would be an intuitive alternative to PPD. But previous research has found that the pigment molecules clump together, forming rods and spheres too large to penetrate into the hair shaft to create lasting color. Jong-Rok Jeon and colleagues wanted to build on the idea of using melanin but with a molecule that mimics the real thing. The researchers turned to polydopamine, a black substance that is structurally similar to melanin and has been explored for use in a variety of biomedical applications. Polydopamine with iron ions transformed gray hairs into black and lasted through three wash cycles. Lighter shades could also be achieved with polydopamine by pairing it with copper and aluminum ions. And toxicity tests showed that mice treated with the colorant didn't have noticeable side effects, while those that received a PPD-based dye developed bald spots. Explore further: Hair dyeing poised for first major transformation in 150 years More information: Kyung Min Im et al. Metal-Chelation-Assisted Deposition of Polydopamine on Human Hair: A Ready-to-Use Eumelanin-Based Hair Dyeing Methodology, ACS Biomaterials Science & Engineering (2017). DOI: 10.1021/acsbiomaterials.7b00031 Abstract Permanent dyeing of gray hair has become an increasingly active area in the cosmetics industry because of the increasingly aging population in developed countries. So far, p-phenylenediamine (PPD) and related diamine-based monomeric compounds have been widely used for the dyeing processes, but toxicological studies have revealed such compounds to be carcinogenic and allergenic. Here, we for the first time demonstrated that polydopamine, a mimic of human eumelanin, gives rise within a commercially acceptable period of time (i.e., 1 h) to deep black colors (i.e., natural Asian hair colors) in human keratin hairs in the presence of ferrous ions. The dyed hairs showed excellent resistance to conventional detergents, and the detailed color was readily varied by changing the kind of metal ion used. SEM images and FT-IR-ATR spectra suggested that the extent of polydopamine aggregation was crucial for the dyeing efficiency. High-resolution (15 T) FT-ICR mass spectrometry performed on the products detached from hairs with either 0.1 N HCl or NaOH indicated that similar polydopamine products were recruited into the hair matrices whether in the presence or absence of metal-based chelating. Polydopamine chains were determined using EPR and ICP-OES to use chelation of ferrous ions to self-assemble as well as to bind keratin surfaces in the dyeing conditions. Also, mice subjected to skin toxicity tests showed much greater viability and much less hair loss with our dyeing agents than with PPD. In conclusion, this study showed that a safe eumelanin mimic may be used to permanently dye gray hair, and showed three kinds of deposition mechanisms (i.e., innate binding ability of polydopamine, metal-assisted self-assembly of polydopamine, and metal-related bridging between keratin surface and polydopamine) to be involved.


SINGAPORE--(BUSINESS WIRE)--A.M. Best has placed under review with developing implications the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating (Long-Term ICR) of “a-” of TOWER Insurance Limited (TIL). A.M. Best also has placed under review with developing implications the Long-Term ICR of “bbb-” of TIL’s ultimate parent, TOWER Limited (TL). Both companies are domiciled in New Zealand. The Credit Rating (rating) actions follow the announcement that TL and Fairfax Financial Holdings Limited (Fairfax) have entered into an agreement under which Fairfax will acquire 100% of TL shares at NZD 1.17 per share, for an aggregate purchase price of NZD 197 million. The ratings will remain under review until the close of the transaction, and until A.M. Best completes its discussions with the Fairfax management team. Any potential rating impact from actual or anticipated changes to TL’s and TIL’s credit profiles also will be assessed. Additionally, A.M. Best will factor its view of the extent of Fairfax’s financial support into the final rating determination. Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication. This press release relates to Credit Ratings that have been published on A.M. Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see A.M. Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Understanding Best’s Credit Ratings. A.M. Best is the world’s oldest and most authoritative insurance rating and information source. For more information, visit www.ambest.com. Copyright © 2017 by A.M. Best Rating Services, Inc. and/or its subsidiaries. ALL RIGHTS RESERVED.

Loading ICR collaborators
Loading ICR collaborators